Skip to main content
SpringerLink
Log in

Aktuelle Behandlungsmöglichkeiten akuter myeloischer Leukämien

Current treatment options in acute myeloid leukemia

  • Schwerpunkt
  • Published:
Der Internist Aims and scope Submit manuscript

Zusammenfassung

Bei der akuten myeloischen Leukämie (AML) spielen genetische Veränderungen mittlerweile eine zentrale Rolle in der diagnostischen Kategorisierung entsprechend der aktuellen Klassifikation der World Health Organization. Sie sind darüber hinaus die entscheidenden prognostischen Faktoren für die Vorhersage des Ansprechens auf eine intensive Induktionschemotherapie und das rezidivfreie Überleben sowie das Gesamtüberleben. Die große Bedeutung der zytogenetischen und molekulargenetischen Veränderungen in der Pathogenese der AML spiegeln sich zunehmend in individualisierten Therapiestrategien für einzelne Patienten wider. Das molekulare Profil der Erkrankung ist mittlerweile unverzichtbar für die Auswahl der besten Therapiestrategie.

Abstract

Genetic aberrations form the basis for diagnostic classification of patients with acute myeloid leukemia (AML) according to the World Health Organization (WHO) classification. Moreover, these aberrations predict response to induction chemotherapy, relapse-free survival, and overall survival of patients with AML. Understanding the pathogenetic role of cytogenetic and molecular changes has led to the development of targeted treatment strategies that require rapid diagnostic assessment of the genetic profile of each patient to select the best treatment available.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Arber DA, Vardiman JW, Brunning RD et al (2008) Acute myeloid leukaemia with recurrent genetic abnormalities. In: Swerdlow SH, Campo E, Harris NL et al (Hrsg) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. WHO PRESS, Geneva, Switzerland

  2. Becker H, Marcucci G, Maharry K et al (2010) Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol 28:596–604

    Article  PubMed  CAS  Google Scholar 

  3. Buchner T, Berdel WE, Haferlach C et al (2009) Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 27:61–69

    Article  PubMed  Google Scholar 

  4. Burnett A, Wetzler M, Lowenberg B (2011) Therapeutic advances in acute myeloid leukemia. J Clin Oncol 29:487–494

    Article  PubMed  Google Scholar 

  5. Burnett AK, Hills RK, Milligan D et al (2011) Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 29:369–377

    Article  PubMed  CAS  Google Scholar 

  6. Burnett AK, Milligan D, Prentice AG et al (2007) A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 109:1114–1124

    Article  PubMed  CAS  Google Scholar 

  7. Burnett AK, Russell NH, Kell J et al (2010) European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 28:2389–2395

    Article  PubMed  CAS  Google Scholar 

  8. Damm F, Heuser M, Morgan M et al (2011) Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood 29:682–689

    CAS  Google Scholar 

  9. Delhommeau F, Dupont S, Della Valle V et al (2009) Mutation in TET2 in myeloid cancers. N Engl J Med 360:2289–2301

    Article  PubMed  Google Scholar 

  10. Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223–232

    Article  PubMed  CAS  Google Scholar 

  11. Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al (2010) Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 28:562–569

    Article  PubMed  CAS  Google Scholar 

  12. Fernandez HF, Sun Z, Yao X et al (2009) Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 361:1249–1259

    Article  PubMed  CAS  Google Scholar 

  13. Giles FJ, Borthakur G, Ravandi F et al (2007) The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 136:624–627

    Article  PubMed  Google Scholar 

  14. Juliusson G, Antunovic P, Derolf A et al (2009) Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 113:4179–4187

    Article  PubMed  CAS  Google Scholar 

  15. Kantarjian H, Ravandi F, O’Brien S et al (2010) Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 116:4422–4429

    Article  PubMed  CAS  Google Scholar 

  16. Koreth J, Schlenk R, Kopecky KJ et al (2009) Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 301:2349–2361

    Article  PubMed  CAS  Google Scholar 

  17. Krug U, Rollig C, Koschmieder A et al (2010) Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet 376:2000–2008

    Article  PubMed  CAS  Google Scholar 

  18. Lee JH, Joo YD, Kim H et al (2011) A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood 118:3832–3841

    Article  PubMed  CAS  Google Scholar 

  19. Lowenberg B, Ossenkoppele GJ, Putten W van et al (2009) High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 361:1235–1248

    Article  PubMed  Google Scholar 

  20. Lowenberg B, Zittoun R, Kerkhofs H et al (1989) On the value of intensive remission-induction chemotherapy in elderly patients of 65 + years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 7:1268–1274

    PubMed  CAS  Google Scholar 

  21. Mayer RJ, Davis RB, Schiffer CA et al (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331:896–903

    Article  PubMed  CAS  Google Scholar 

  22. Menzin J, Lang K, Earle CC et al (2002) The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 162:1597–1603

    Article  PubMed  Google Scholar 

  23. Paschka P, Schlenk RF, Gaidzik VI et al (2010) IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 28:3636–3643

    Article  PubMed  CAS  Google Scholar 

  24. Pautas C, Merabet F, Thomas X et al (2010) Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50–70 years: results of the ALFA-9801 study. J Clin Oncol 28:808–814

    Article  PubMed  CAS  Google Scholar 

  25. Rollig C, Thiede C, Gramatzki M et al (2010) A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood 116:971–978

    Article  PubMed  Google Scholar 

  26. Schlenk RF, Dohner K, Kneba M et al (2009) Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica 94:54–60

    Article  PubMed  CAS  Google Scholar 

  27. Schlenk RF, Dohner K, Krauter J et al (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358:1909–1918

    Article  PubMed  CAS  Google Scholar 

  28. Schlenk RF, Dohner K, Mack S et al (2010) Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol 28:4642–4648

    Article  PubMed  Google Scholar 

  29. Schlenk RF, Ganser A, Dohner K (2010) Prognostic and Predictive effect of molecular and cytogenetic aberrations in acute myeloid leukemia. ASCO Educ Book 2010:228–232

    Google Scholar 

  30. Stone RM, Fischer T, Paquette R et al (2009) A Phase 1b study of midostaurin (PKC412) in combination with daunorubicin and cytarabine induction and high-dose cytarabine consolidation in patients under age 61 with newly diagnosed de novo acute myeloid leukemia: Overall survival of patients whose blasts have FLT3 mutations is similar to those with wild-type FLT3. Blood 114:634 (abstract)

    Article  Google Scholar 

  31. Taskesen E, Bullinger L, Corbacioglu A et al (2011) Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 117:2469–2475

    Article  PubMed  CAS  Google Scholar 

  32. Thol F, Damm F, Lüdeking A et al (2011) Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 29:2889–2896

    Article  PubMed  CAS  Google Scholar 

  33. Thol F, Damm F, Wagner K et al (2010) Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 116:614–616

    Article  PubMed  CAS  Google Scholar 

  34. Wagner K, Damm F, Gohring G et al (2010) Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol 28:2356–2364

    Article  PubMed  CAS  Google Scholar 

  35. Wheatley K, Brookes CL, Howman AJ et al (2009) Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol 145:598–605

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Medizinische Hochschule Hannover, Carl-Neuberg Straße 1, 30625, Hannover, Deutschland

    M. Heuser & A. Ganser

  2. Klinik für Innere Medizin III, Universitätsklinikum Ulm, Ulm, Deutschland

    R.F. Schlenk

Authors
  1. M. Heuser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R.F. Schlenk
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Ganser
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Heuser.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Heuser, M., Schlenk, R. & Ganser, A. Aktuelle Behandlungsmöglichkeiten akuter myeloischer Leukämien. Internist 52, 1386–1393 (2011). https://doi.org/10.1007/s00108-011-2929-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-011-2929-x

Schlüsselwörter

Keywords

Search

Navigation